Mitral stenosis resident survival guide: Difference between revisions
Line 74: | Line 74: | ||
==Management== | ==Management== | ||
Shown below is an algorithm summarizing the approach to management of mitral stenosis according to 2014 AHA/ACC guidelines for management of valvular heart disease.<ref name="pmid24589852">{{cite journal| author=Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA et al.| title=2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2014 | volume= | issue= | pages= | pmid=24589852 | doi=10.1161/CIR.0000000000000029 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24589852 }} </ref> | |||
{{familytree/start |summary=PE diagnosis Algorithm.}} | {{familytree/start |summary=PE diagnosis Algorithm.}} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
Line 82: | Line 83: | ||
{{familytree | | | | | | D01 | | | | | | | | | | | | | | | | D02 | | | | | | | |D01=❑ Assess the severity of [[mitral stenosis]]|D02=❑ Assess the severity of [[mitral stenosis]]}} | {{familytree | | | | | | D01 | | | | | | | | | | | | | | | | D02 | | | | | | | |D01=❑ Assess the severity of [[mitral stenosis]]|D02=❑ Assess the severity of [[mitral stenosis]]}} | ||
{{familytree | | |,|-|-|-|+|-|-|-|.| | | | | |,|-|-|-|-|-|-|-|+|-|-|-|-|-|.| | | | | | }} | {{familytree | | |,|-|-|-|+|-|-|-|.| | | | | |,|-|-|-|-|-|-|-|+|-|-|-|-|-|.| | | | | | }} | ||
{{familytree | | C01 | | C02 | | C03 | | | | | {{familytree | | C01 | | C02 | | C03 | | | | C04 | | | | | | C05 | | | | C06 | | | | | |C01=<div style="float: left; text-align: left; width: 8em; padding:1em;">'''Very severe'''<br>❑ MVA ≤ 1 cm<sup>2</sup><br>❑ Pressure half time ≥ 220 ms<br>❑ [[Mitral stenosis stages|Stage D]]</div>|C02=<div style="float: left; text-align: left; width: 8em; padding:1em;">'''Severe'''<br>❑ MVA ≤ 1.5 cm<sup>2</sup><br>❑ Pressure half time ≥ 150 ms<br>❑ [[Mitral stenosis stages|Stage D]]</div>|C03=<div style="float: left; text-align: left; width: 8em; padding:1em;">'''Progressive'''<br>❑ MVA > 1.5 cm<sup>2</sup><br>Pressure half time < 150 ms </div>|C04=<div style="float: left; text-align: left; width: 8em; padding:1em;">'''Very severe'''<br>❑ MVA ≤ 1 cm<sup>2</sup><br>❑ Pressure half time ≥ 220 ms<br>❑ [[Mitral stenosis stages|Stage C]]</div>|C05=<div style="float: left; text-align: left; width: 8em; padding:1em;">'''Severe'''<br>❑ MVA ≤ 1.5 cm<sup>2</sup><br>❑ Pressure half time ≥ 150 ms<br>❑ [[Mitral stenosis stages|Stage C]]</div>|C06=<div style="float: left; text-align: left; width: 8em; padding:1em;">'''Progressive'''<br>❑ MVA > 1.5 cm<sup>2</sup><br>Pressure half time < 150 ms </div>}} | ||
{{familytree | | |`|-|v|-|'| | | |!| | | | | |!| | | | | | | |!| | | | | |!| | | | | }} | {{familytree | | |`|-|v|-|'| | | |!| | | | | |!| | | | | | | |!| | | | | |!| | | | | }} | ||
{{familytree | | | | D01 | | | | D02 | | | | D03 | | | | | | D04 | | | | D05 | | | | | | | |D01= <div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if valve morphology is favorable for [[PMBV|PMBC]]</div>|D02=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Perform exercise testing </div>|D03=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if valve morphology is favorable for [[PMBV|PMBC]]</div>|D04=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if valve morphology is favorable for [[PMBV|PMBC]]</div>|D05=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Monitor patient periodically</div>}} | {{familytree | | | | D01 | | | | D02 | | | | D03 | | | | | | D04 | | | | D05 | | | | | | | |D01= <div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if valve morphology is favorable for [[PMBV|PMBC]]</div>|D02=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Perform [[exercise testing]] </div>|D03=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if valve morphology is favorable for [[PMBV|PMBC]]</div>|D04=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if valve morphology is favorable for [[PMBV|PMBC]]</div>|D05=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Monitor patient periodically</div>}} | ||
{{familytree | |,|-|-|^|.| | | | |!| | | | | |)|-|-|-|.| | | |)|-|-|-|.| | | | | | | }} | {{familytree | |,|-|-|^|.| | | | |!| | | | | |)|-|-|-|.| | | |)|-|-|-|.| | | | | | | }} | ||
{{familytree | E01 | | E02 | | | E03 | | | | E04 | | E05 | | E06 | | E07 | | | |E01=Yes|E02=No|E03=❑ Assess if [[PCWP]] > 25 mm Hg on exercise|E04=Yes|E05=No|E06=No|E07=Yes}} | {{familytree | E01 | | E02 | | | E03 | | | | E04 | | E05 | | E06 | | E07 | | | |E01=Yes|E02=No|E03=❑ Assess if [[PCWP]] > 25 mm Hg on exercise|E04=Yes|E05=No|E06=No|E07=Yes}} | ||
{{familytree | |!| | | |!| | | | |!| | | | | |!| | | |`|-|v|-|'| | | |!| | | | | }} | {{familytree | |!| | | |!| | | | |!| | | | | |!| | | |`|-|v|-|'| | | |!| | | | | }} | ||
{{familytree | F01 | | F02 | | | F03 | | | | F04 | | | | F05 | | | | F06 | | | |F01=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Proceed with [[PMBV|PMBC]] </div>|F02=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if patient is severely symptomatic (NYHA III/IV)<br>❑ Assess if the risk of surgery is high</div>|F03=<div style="float: left; text-align: left; width: 8em; padding:1em;"> | {{familytree | F01 | | F02 | | | F03 | | | | F04 | | | | F05 | | | | F06 | | | |F01=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Proceed with [[PMBV|PMBC]] </div>|F02=<div style="float: left; text-align: left; width: 8em; padding:1em;">❑ Assess if patient is severely symptomatic ([[NYHA class|NYHA III/IV]])<br>❑ Assess if the risk of surgery is high</div>|F03=<div style="float: left; text-align: left; width: 8em; padding:1em;">'''If [[PCWP]] > 25 mm Hg:'''<br> ❑ Proceed with [[PMBV|PMBC]] <br>'''If [[PCWP]]< 25 mm Hg''' :<br>❑ Monitor patient periodically </div>|F04=❑ Proceed with [[PMBV|PMBC]]|F05=❑ Monitor patient periodically|F06=❑ Assess for the presence of new onset [[AF]]|F07=❑ Monitor patient periodically}} | ||
{{familytree | | | |,|-|^|-|.| | | | | | | | | | | | | | | | | | |,|-|^|-|.| | | }} | {{familytree | | | |,|-|^|-|.| | | | | | | | | | | | | | | | | | |,|-|^|-|.| | | }} | ||
{{familytree | | | G01 | | G02 | | | | | | | | | | | | | | | | | G03 | | G04 | |G01= Yes|G02=No|G03=[[AF]] present|G04= No [[AF]]}} | {{familytree | | | G01 | | G02 | | | | | | | | | | | | | | | | | G03 | | G04 | |G01= Yes|G02=No|G03=[[AF]] present|G04= No [[AF]]}} | ||
{{familytree | | | |!| | | |!| | | | | | | | | | | | | | | | | | |!| | | |!| | | }} | {{familytree | | | |!| | | |!| | | | | | | | | | | | | | | | | | |!| | | |!| | | }} | ||
{{familytree | | | H01 | | H02 | | | | | | | | | | | | | | | | | H03 | | H04 | |H01=❑ Proceed with [[PMBV|PMBC]] |H02=❑ Proceed with [[mitral valve surgery]]|H03=❑ Proceed with [[PMBV|PMBC]]|H04=❑ Monitor patient periodically }} | {{familytree | | | H01 | | H02 | | | | | | | | | | | | | | | | | H03 | | H04 | |H01=❑ Proceed with [[PMBV|PMBC]] |H02=❑ Proceed with [[mitral valve surgery]]|H03=❑ Proceed with [[PMBV|PMBC]]|H04=❑ Monitor patient periodically }} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
{{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | {{familytree | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | }} | ||
{{familytree/end}} | {{familytree/end}} | ||
<span style="font-size:85%">'''MVA''': Mitral valve area; '''PMBC''': Percutaneous mitral ballon commissurotomy; '''PCWP''': Pulmonary capillary wedge pressure; '''ms''': milliseconds; '''NYHA''': New York Heart Association; '''AF''': Atrial fibrillation </span> <br> | |||
==Additional Management== | ==Additional Management== |
Revision as of 23:25, 10 March 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Definition
Mitral stenosis refers to abnormal narrowing of mitral orifice which leads to obstruction of blood flow from left atrium to left ventricle and development of a pressure gradient between the two chambers.
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Initial Evaluation
Shown below is an algorithm summarizing the approach to [[disease name]].
Characterize the symptoms: ❑ Exercise intolerance | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient:
Head:
Neck: Chest:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Management
Shown below is an algorithm summarizing the approach to management of mitral stenosis according to 2014 AHA/ACC guidelines for management of valvular heart disease.[2]
❑Assess the presence of symptoms | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Symptomatic | Asymptomatic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess the severity of mitral stenosis | ❑ Assess the severity of mitral stenosis | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Progressive ❑ MVA > 1.5 cm2 Pressure half time < 150 ms | Progressive ❑ MVA > 1.5 cm2 Pressure half time < 150 ms | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Assess if valve morphology is favorable for PMBC | ❑ Perform exercise testing | ❑ Assess if valve morphology is favorable for PMBC | ❑ Assess if valve morphology is favorable for PMBC | ❑ Monitor patient periodically | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | ❑ Assess if PCWP > 25 mm Hg on exercise | Yes | No | No | Yes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Proceed with PMBC | ❑ Assess if patient is severely symptomatic (NYHA III/IV) ❑ Assess if the risk of surgery is high | ❑ Proceed with PMBC | ❑ Monitor patient periodically | ❑ Assess for the presence of new onset AF | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Yes | No | AF present | No AF | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Proceed with PMBC | ❑ Proceed with mitral valve surgery | ❑ Proceed with PMBC | ❑ Monitor patient periodically | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
MVA: Mitral valve area; PMBC: Percutaneous mitral ballon commissurotomy; PCWP: Pulmonary capillary wedge pressure; ms: milliseconds; NYHA: New York Heart Association; AF: Atrial fibrillation
Additional Management
Medical therapy ❑ Consider heart rate control in MS patients with:
❑ Consider anticoagulation therapy in MS patients with:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Do's
Dont's
References
- ↑ Tadele, H.; Mekonnen, W.; Tefera, E. (2013). "Rheumatic mitral stenosis in Children: more accelerated course in sub-Saharan Patients". BMC Cardiovasc Disord. 13 (1): 95. doi:10.1186/1471-2261-13-95. PMID 24180350. Unknown parameter
|month=
ignored (help) - ↑ Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP, Guyton RA; et al. (2014). "2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0000000000000029. PMID 24589852.